Company Overview and News

13
SL Green Revamps Portfolio Through Strategic Dispositions

2018-06-05 zacks
SL Green Realty (SLG - Free Report) is disposing its stake in a joint venture asset and redeeming its investment in a property. These retail transactions are in line with the company’s efforts to improve its overall portfolio mix and enhance shareholders value. Particularly, the company entered into an agreement to sell its ownership stake at 724 Fifth Avenue to its joint venture partner, Jeff Sutton.
ABR ABRN DB SLG.PRI ABRN.CL CXP ABR.PRB ABR.PRC SLG ABR.PRA

0
CXP / Columbia Property Trust, Inc. DEFA14A

2018-05-08 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CXP

0
CXP / Columbia Property Trust, Inc. DEFA14A

2018-05-04 sec.gov
Document UNITED STATES
CXP

0
Columbia Property Trust's (CXP) CEO Nelson Mills on Q1 2018 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Good afternoon and welcome to the Columbia Property Trust First Quarter 2018 Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
CXP

0
CXP / Columbia Property Trust, Inc. 10-Q (Quarterly Report)

2018-04-27 sec.gov
Document Table of Contents
CXP

28
Columbia Property Trust, Inc. (CXP) Sees Hammer Chart Pattern: Time to Buy?

2018-04-11 zacks
Columbia Property Trust, Inc. (CXP - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because CXP recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
WFC WFCNP WFC.WS VOD VOD WFC.PRL CXP WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO VODPF WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

0
CXP / Columbia Property Trust, Inc. DEFA14A

2018-03-30 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CXP

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 198287203